Insulin-sensitisers in the treatment of polycystic ovary syndrome

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 14, 2005, Pages 2419-2427

  Teede, Helena J ^a   Meyer, C ^b   Norman, R J ^c  

^a Jean Hailes Foundation for Women's Health   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Insulin resistance; Metformin; Oral contraceptives; Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIDIABETIC AGENT; DIAZOXIDE; INOSITOL DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SOMATOSTATIN; SPIRONOLACTONE; TROGLITAZONE;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; FEMALE; FERTILITY; GASTROINTESTINAL SYMPTOM; HEREDITY; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIFESTYLE; LIVER TOXICITY; NAUSEA; NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RISK BENEFIT ANALYSIS;

BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIET; DRUG APPROVAL; EXERCISE; FEMALE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MENSTRUAL CYCLE; METFORMIN; OBESITY; OVULATION; POLYCYSTIC OVARY SYNDROME; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; THIAZOLIDINEDIONES;

EID: 28244449607     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.14.2419     Document Type: Review

References (76)

1. AZZIZ R, WOODS K, REYNA R et al.: The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. (2004) 89:2745-2749.
2. KNOCHENHAUER ES, KEY TJ, KAHSAR-MILLER M et al.: Prevalence of the polycystic ovary syndrome in unselected black and white women of the south eastern United States. A prospective study. J. Clin. Endocrinol. Metab. (1998) 83(9):3078-3084.
3. DIAMANTI-KANDARAKIS E, KOULI CR, BERGIELE AT et al.: A survey of the polycystic ovary syndrome in the Greek island of Lesbos. Hormonal and metabolic profile. J. Clin. Endocrinol. Metab. (1999) 84(11):4006-4011.
4. ZAWADZKI J, DUNAIF A: Diagnostic criteria for polycystic ovary syndrome. Towards a rational approach. In: Polycystic Ovary Syndrome. Dunaif A, Givens J (Eds). Blackwell, Cambridge, MA (1992):377-384.
5. ROTTERDAM ESHRE/ASRM-SPONSORED PCOS CONSENSUS WORKSHOP GROUP: Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil. Steril. (2004) 81(1):19-25.
6. NORMAN RJ, MASTERS SC, HAGUE W et al.: Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertil. Steril. (1995) 63(2):329-335.
7. DUNAIF A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. (1997) 18(6):774-800.
8. NESTLER JE, JAKUBOWICZ DJ: Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J. Clin. Endocrinol. Metab. (1997) 82(12):4075-4079.
9. DE LEO V, LA MARCA A, PETRAGLIA F: Insulin-lowering agents in the management of polycystic ovary syndrome. Endocrine Rev. (2003) 24(5):633-667.
10. NHMRC: Clinical practise guidelines for the management of overweight and obesity in adults. NHMRC Clinical Practise Guidelines. (2003):xiii.
11. MORAN LJ, NOAKES M, CLIFTON PM et al.: Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2003) 88(2):812-819.
12. HOLTE J, BERGH T, BERNE C et al.: Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (1995) 80:2586-2593.
13. MORIN-PAPUNEN LC, VAUHKONEN I, KOIVUNEN RM et al.: Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab. (2000) 85(9):3161-3168.
14. CREATAS G, KOLIOPOULOS C, MASTORAKOS G: Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Annal. New York Acad. Scien. (2000) 900:245-252.
15. GODSLAND IF, CROOK D, SIMPSON R et al.: The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N. Engl. J. Med. (1990) 323:1375-1380.
16. ESCOBAR-MORREALE HF, MIGUEL L, JOSE S: Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fert. Ster. (2000) 74(4):816-819.
17. MEYER C, MCGRATH B, TEEDE H: Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J. Clin. Endocrinol. Metab. (in press).
18. LORD JM, FLIGHT IH, NORMAN RJ: Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev. (2003) 3:CD003053.
19. KNOWLER W, BARRETT-CONNOR E, FOWLER S et al.: Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. New. Eng. J. Med. (2002) 346(6):393-403.
20. VELAZQUEZ E, MENDOSA S, HAMER T et al.: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism (1994) 43:647-654.
21. MOGHETTI P, CASTELLO R, NEGRI C et al.: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. (2000) 85(1):139-146.
22. PIRWANY I, TULANDI T. Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure? Fertil. Steril. (2003) 80(2):241-251.
23. GLUECK CJ, GOLDENBERG N, STREICHER P et al.: Metformin and gestational diabetes. Current Diabetes Reports. (2003) 3(4):303-312.
24. GLUECK CJ, WANG P, KOBAYASHI S et al.: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil. Steril. (2002) 77(3):520-525,.
25. GLUECK CJ, GOLDENBERG N, PRANIKOFF J et al.: Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum. Reprod. (2004) 19(6):1323-1330.
26. CARMINA E: Anti-androgens for the treatment of hirsutism. Expert Opin. Investig. Drugs (2002) 11(3):357-363.
27. YILDIZ B: Recent advances in the treatment of polycystic ovarian syndrome. Expert Opin. Investig. Drugs (2004) 13(10):1295-1305.
28. ELTER K, IMIR G, DURMUSOGLU F: Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomised controlled study. Human Reprod. (2002) 17(7):1729-1737.
29. GANIE MA, KHURANA ML, EUNICE M et al.: Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J. Clin. Endocrinol. Metab. (2004) 89(6):2756-2762.
30. CHOU KH, VON EYE CORLETA H, CAPP E et al.: Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm. Metab. Res. (2003) 35(2):86-91.
31. YARALI H, YILDIZ BO, DEMIROL A et al.: Co-administration of metformin during FSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum. Reprod. (2002) 17(2):289-294.
32. NESTLER JE, JAKUBOWICZ DJ: Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med (1996) 335(9):617-623.
33. PASQUALI R, GAMBINERI A, BISCOTTI D et al.: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2000) 85(8):2767-2175.
34. HARBORNE L, FLEMING R, LYALL H et al.: Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2003) 88:4166-4123.
35. BRAY G: Medical consequences of obesity. J. Clin. Endocrinol. Metab. (2004) 89:2583-2589.
36. CHAN J, RIMM E, COLDITZ G et al.: Obesity, fat distribution and weight gain as risk factors for clinical diabetes in men. Diab. Care (1994) 17:961-969.
37. FLEMING R, HOPKINSON ZE, WALLACE AM et al.: Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J. Clin. Endocrinol. Metab. (2002) 87(2):569-574.
38. DIAMANTI-KANDARAKIS E, KOULI C, TSIANATELI T et al.: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. J. Endocrinol. (1998) 138(3):269-274.
39. SAMPSON M, KONG C, PATEL A, UNWIN R, JACOBS HS: Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin. Endocrinol. (1996) 45(5):623-629.
40. HOLTE J, GENNARELLI G, BERNE C, BERGH T, LITHELL H: Elevated daytime blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Human Reprod. (1996) 11:23-28.
41. HACIHANEFIOGLU B, SOMUNKIRAN A, MAHMUTOGLU I, SERCELIK A, TOPTANI S, KERVANCIOGLU E: Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome. Fertil. Steril. (2002) 77(3):526-528.
42. MEYER C, MC GRATH B, CAMERON J, KOTSOPOULOS D, TEEDE HJ: Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (in press).
43. O'MEARA N, BLACKMAN J, EHRMANN D et al.: Defects in beta-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. (1993) 76(5):1241-1288.
44. DUNAIF A, SEGAL K, FUTTERWEIT W, DOBRJANSKY A: Profound insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes (1989) 38:1165.
45. FOX JH, LICHOLAI T, GREEN G, DUNAIF A: Differential effects of oral glucose-mediated versus intravenous hyperinsulinemia on circulating androgen levels in women. Fertil. Steril. (1993) 60(6):994-1000.
46. DUNAIF A, SCOTT D, FINEGOOD D, QUINTANA B, WHITCOMB R: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (1996) 81(9):3299-3306.
47. VELAZQUEZ E, ACOSTA A, MENDOSA S: Menstrual cyclicity after metformin therapy in polycystic ovarian syndrome. Obstet. Gynecol. (1997) 90:392-395.
48. DUNAIF A, FINEGOOD D: Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (1996) 81(3):942-948.
49. O'MEARA NM, BLACKMAN JD, EHRMANN DA et al.: Defects in beta-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. (1993) 76(5):1241-1247.
50. LEGRO RS, KUNSELMAN AR, DODSON WC, DUNAIF A: Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. (1999) 84(1):165-168.
51. NORMAN RJ, MASTERS L, MILNER CR, WANG JX, DAVIES MJ: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum. Reprod. (2001) 16(9):1995-1998.
52. PIERPOINT T, MCKEIGUE P, ISAACS A, WILD S, JACOBS H: Mortality of women with polycystic ovary syndrome at long term follow-up. J. Clin. Epidemiol. (1998) 51(7):581-586.
53. WILD S, PIERPOINT T, MCKEIGUE P, JACOBS H: Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin. Endocrinol. (2000) 52:595-600.
54. KATZ A, NAMBI SS, MATHER K et al.: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. (2000) 85(7):2402-2410.
55. RADZIUK J: Insulin sensitivity and its measurement: Structural commonalities among the methods. J. Clin. Endocrinol. Metab. (2000) 85(12):4426-4433.
56. PHILLIPS D, CLARK P, HALES C, OSMOND C: Understanding oral glucose tolerance:comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and secretion. Diab. Med. (1994) 11:286-292.
57. BONORA E, TARGHER G, ALBERICHIE M, BONADONNA R, SAGGIANNI F, ZENERE M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitvity. Diab. Care (2000) 23(1):57-63.
58. HERMANS M, LEVY J, MORRIS R, TURNER R: Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia (1999) 42:678-687.
59. DIAMANTI-KANDARAKIS E, KOULI C, ALEXANDRAKI K, SPINA G: Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2004) 89(3):1273-1276.
60. ARSLANIAN SA, LEWY V, DANADIAN K, SAAD R: Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J. Clin. Endocrinol. Metab. (2002) 87(4):1555-1559.
61. EHRMANN DA, CAVAGHAN MK, IMPERIAL J, STURIS J, ROSENFIELD RL, POLONSKY KS: Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (1997) 82(2):524-530.
62. WILD R, PAINTER P, COULSON P, CARRUTH K, RANNEY G: Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. (1985) 61:946-951.
63. WILD RA: Obesity, lipids, cardiovascular risk, and androgen excess. Am. J. Med. (1995) 98(1A):27S-32S.
64. TALBOT E, CLERICI A, BERGA S: Adverse lipid and coronary heart disease profiles in young women with polycystic ovary syndrome: results of a case control study. J. Clin. Epidemiology (1998) 51:415-422.
65. IBANEZ L, VALLS C, POTAU N, MARCOS MV, DE ZEGHER F: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J. Clin. Endocrinol. Metab. (2000) 85(10):3526-3530.
66. BEDAIWWY MA, MILLER KF, GOLDBERG JM, NELSON D, FALCONE T: Effect of metformin on mouse embryo development. Fertil. Steril. (2001) 76:1078-1079..
67. SALPETER S, GREYBER E, PASTERNAK G, SALPETER E: Risk of fatal and nonfatal lactic acidosis with Metformin use in Type II diabetes mellitus. Arch. Int. Med. (2003) 163(21):2594-2602.
68. YKI-JARVINEN H: Drug therapy: thiazolidinediones. N. Engl. J. Med. (2004) 351(11):1106-1118.
69. AZZIZ R, EHRMANN D, LEGRO RS et al.: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. (2001) 86(4):1626-1632.
70. PARADISI G, STEINBERG H, SHEPARD M, HOOK G, BARON AD: Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2003) 88:576-580.
71. SEPILIAN V, NAGAMANI M: Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J. Clin. Endocrinol. Metab. (2005) 90(1):60-65.
72. GHAZEERI G, KUTTEH WH, BRYER-ASH M, HAAS D, KE RW: Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril. (2003) 79(3):562-566.
73. ROMUALDI D, GUIDO M, CIAMPELLI M et al.: Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Human Reprod. (2003) 18(6):1210-1218.
74. BAILLARGEON JP, JAKUBOWICZ DJ, IUORNO MJ, JAKUBOWICZ S, NESTLER JE: Effects of metformin and rosiglitazone, alone and in combination, in non obese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil. Steril. (2004) 82(4):893-902.
75. BRETTENTHALER N, DE GEYTER C, HUBER PR, KELLER U: Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2004) 18(8):3835-3840.
76. GLUECK CJ, MOREIRA A, GOLDENBERG N, SIEVE L, WANG P: Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Human Reprod. (2003) 18(8):1618-1625.